MediWound Posts Early Data From Non-Melanoma Skin Cancer Trial

MediWound Ltd  (NASDAQ: MDWD ) announced initial data  from eleven patients in its ongoing open-label Phase 1/2 study of MW005 for low-risk Basal Cell Carcinoma (BCC).  The initial data shows MW005 to be safe and well-tolerated, with most of the patients who completed the study achieving complete histological clearance of their ... Full story available on